ZMS1012

Anti-APP A4 Antibody, clone 22C11 ZooMAb^® Mouse Monoclonal

recombinant, expressed in HEK 293 cells

• Synonym(s): Amyloid-beta A4 protein;ABPP;APPI;APP;Alzheimer disease amyloid protein;Amyloid precursor protein;Amyloid-beta precursor protein;Cerebral vascular amyloid peptide;CVAP;PreA4;Protease nexin-II;PN-II
• UNSPSC Code: 12352203

Properties

• biological source: mouse
• Quality Level: 200
• recombinant: expressed in HEK 293 cells
• conjugate: unconjugated
• antibody form: purified antibody
• antibody product type: primary antibodies
• clone: 22C11, recombinant monoclonal
• product line: ZooMAb^® learn more
• form: lyophilized
• mol wt: calculated mol wt 86.94 kDa; observed mol wt ~110 kDa
• purified by: using Protein A
• species reactivity: rat, mouse, human
• species reactivity (predicted by homology): porcine, monkey, canine
• packaging: antibody small pack of 25 μL
• greener alternative product characteristics: Waste Prevention; Designing Safer Chemicals; Design for Energy Efficiency; Learn more about the Principles of Green Chemistry.
• enhanced validation: recombinant expression; Learn more about Antibody Enhanced Validation
• technique(s): immunocytochemistry: suitable; immunohistochemistry: suitable; western blot: suitable
• isotype: IgG1
• epitope sequence: N-terminal
• Protein ID accession no.: NM_000484.2
• UniProt accession no.: P05067
• greener alternative category: Aligned,
• shipped in: ambient
• storage temp.: 2-8°C
• target post-translational modification: unmodified
• Gene Information: human ... APP(351)

Description

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Specificity

Clone 22C11 is a ZooMAb^® mouse recombinant monoclonal antibody that detects Amyloid precursor A4 protein. It targets an epitope within 16 amino acids from the N-terminal region.

Immunogen

Recombinant bacterial expressed APP A4 (pre A4(695)) fusion protein.

Application

Quality Control Testing

Evaluated by Western Blotting in Rat brain tissue lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected APP A4 in Rat brain tissue lysate.

Tested applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected APP A4 in lysaates from Human Brain, Mouse Brain, Human Alzheimer Brain, and in U87 cells.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected APP A4 in Human Alzheimer′s disease brain and normal human brain tissue sections.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected APP A4 in SH-SY5Y cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Evaluated by Western Blotting in Rat brain tissue lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected APP A4 in Rat brain tissue lysate.

Target description

Amyloid-beta A4 protein (UniProt: P05067; also known as ABPP, APPI, APP, Alzheimer disease amyloid protein, Amyloid precursor protein, Amyloid-beta precursor protein, Cerebral vascular amyloid peptide, CVAP, PreA4, Protease nexin-II, PN-II) is encoded by the APP (also known as A4, AD1) gene (Gene ID: 351) in human. Deposition of Aβ peptides is an early event in the pathogenesis of Alzheimer s disease (AD) that precedes the formation of Tau-positive paired helical filaments (PHFs) in NFTs. AD is also characterized by a progressive deposition of the Aβ peptide in senile plaques. Aβ peptides originate from the proteolytic cleavage of the amyloid precursor protein (APP). Processing of APP occurs by two major pathways cleavage of APP by -secretase is a non-amyloidogenic pathway and does not produce Aβ peptides. Cleavage of APP at the N-terminus of the Aβ region by β-secretase and at the C-terminus by g-secretase represents the amyloidogenic pathway. The β-secretase cleaves APP between residues Met671 and Asp672 and yields sAPPβ and C99. Following the β-secretase cleavage, a second cleavage occurs at the C-terminus of Aβ peptide that releases Aβ from C99. This cleavage occurs in the vicinity of residue 712 of the C-terminus. The -secretase can cleave the C-terminal region at either Val711 or Ile713 to produce the shorter Aβ peptide (Aβ1-40) or the longer Aβ peptide (Aβ1-42), respectively. The predominant form of Aβ found in the cerebrospinal fluid is the shorter Aβ1-40 peptide. Despite its lower rate of synthesis, Aβ1-42 is the peptide that is initially deposited within the extracellular plaques of AD patients. In addition, Aβ1-42 is more hydrophobic and aggregates at much lower concentration than the Aβ1-40 form. The abnormal accumulation of Aβ peptides can result in neuronal damage and loss by increasing free radical production and activation of inflammatory pathways by enhancing microglial secretion of inflammatory cytokines. Interaction between Aβ and ApoE3 or E4 is also an important determinant of amyloidosis. ApoE3 is shown to inhibit Aβ aggregation in vitro by decreasing Aβ multimers, whereas ApoE4 is reported to accelerate the rate of amyloid fibril formation. This ZooMAbZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Physical form

Purified recombinant mouse monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

Reconstitution

30 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Safety Information

• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 1
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable